Companies
United Therapeutics
pioneering the creation of 3D-printed, transplantable human lungs to cure end-stage pulmonary disease.
- Country
- United States
- Ticker
- UTHR
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Total revenue was approximately $3.2 billion for 2025. | ir.unither.com |
| Capacity | Clinical-scale DPF facility in Virginia has a target capacity of up to 125 organs per year. | corporateresponsibility.unither.com · ir.unither.com |
| Capacity | Starzl Xenograft Production Facility in Stewartville, Minnesota, has a capacity of 150 animals. | postbulletin.com |
| Production site | Designated pathogen-free (DPF) facilities in Virginia, Minnesota, and Texas. | corporateresponsibility.unither.com · ir.unither.com |
| Production site | Organ Manufacturing Group in Manchester, New Hampshire. | ir.unither.com · pipeline.unither.com |
| Production site | Regenerative Medicine Laboratory in Research Triangle Park, North Carolina. | corporateresponsibility.unither.com · ir.unither.com |
| Production site | EVLP facilities in Silver Spring, Maryland and Jacksonville, Florida. | ir.unither.com |
| Headcount | Over 1,400 employees (as of 2025 report/data). | corporateresponsibility.unither.com · ir.unither.com |
| Revenue | Total revenue was approximately $3.2 billion for the year 2025. | ir.unither.com |
| Regulatory approval | FDA-approved therapies include Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, Unituxin, and Adcirca. | ir.unither.com |
| Regulatory approval | First FDA-approved acellular EVLP technology on the market (XPS System with Steen Solution). | ir.unither.com |
Independent sources: corporateresponsibility.unither.com · ir.unither.com · pipeline.unither.com · postbulletin.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Organ & tissue bioprinting | regenerative-personalized | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.